A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

OBJECTIVE CD40-CD40 ligand (CD40L) interactions play a significant role in the production of autoantibodies and tissue injury in lupus nephritis. We performed an open-label, multiple-dose study to evaluate the safety, efficacy, and pharmacokinetics of BG9588, a humanized anti-CD40L antibody, in patients with proliferative lupus nephritis. The primary outcome measure was 50% reduction in proteinuria without worsening of renal function. METHODS Twenty-eight patients with active proliferative lupus nephritis were scheduled to receive 20 mg/kg of BG9588 at biweekly intervals for the first 3 doses and at monthly intervals for 4 additional doses. Safety evaluations were performed on all patients. Eighteen patients receiving at least 3 doses were evaluated for efficacy. RESULTS The study was terminated prematurely because of thromboembolic events occurring in patients in this and other BG9588 protocols (2 myocardial infarctions in this study). Of the 18 patients for whom efficacy could be evaluated, 2 had a 50% reduction in proteinuria without worsening of renal function. Mean reductions of 38.9% (P < 0.005), 50.1% (P < 0.005), and 25.3% (P < 0.05) in anti-double-stranded DNA (anti-dsDNA) antibody titers were observed at 1, 2, and 3 months, respectively, after the last treatment. There was a significant increase in serum C3 concentrations at 1 month after the last dose (P < 0.005), and hematuria disappeared in all 5 patients with significant hematuria at baseline. There were no statistically significant reductions in lymphocyte count or serum immunoglobulin, anticardiolipin antibody, or rubella IgG antibody concentrations after therapy. CONCLUSION A short course of BG9588 treatment in patients with proliferative lupus nephritis reduces anti-dsDNA antibodies, increases C3 concentrations, and decreases hematuria, suggesting that the drug has immunomodulatory action. Additional studies will be needed to evaluate its long-term effects.

[1]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[2]  D. Felson,et al.  Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. , 1984, The New England journal of medicine.

[3]  P H Plotz,et al.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. , 1986, The New England journal of medicine.

[4]  A. Steinberg,et al.  Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. , 1991, Arthritis and rheumatism.

[5]  E. Lewis,et al.  Progression and Remission of Renal Disease in the Lupus Nephritis Collaborative Study , 1992, Annals of Internal Medicine.

[6]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[7]  A. Steinberg,et al.  Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis , 1992, The Lancet.

[8]  E. Lewis,et al.  A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. , 1992, The New England journal of medicine.

[9]  D. Boumpas,et al.  Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy , 1993, Annals of Internal Medicine.

[10]  J. Bajorath,et al.  The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome , 1993, Cell.

[11]  L. Notarangelo,et al.  Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM , 1993, Nature.

[12]  J. Esdaile,et al.  Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. , 1994, The Journal of rheumatology.

[13]  G. Dunea,et al.  The prognosis of lupus nephritis in African-Americans: a retrospective analysis. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  J. Esdaile,et al.  The benefit of early treatment with immunosuppressive agents in lupus nephritis. , 1994, The Journal of rheumatology.

[15]  I. Stamenkovic,et al.  Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis. , 1995, Kidney international.

[16]  C. Mohan,et al.  Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. , 1995, Journal of immunology.

[17]  S. Abramson,et al.  New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis , 1995, Lupus.

[18]  B. Fessler,et al.  Systemic Lupus Erythematosus: Emerging Concepts: Part 1: Renal, Neuropsychiatric, Cardiovascular, Pulmonary, and Hematologic Disease , 1995, Annals of Internal Medicine.

[19]  L. Chess,et al.  Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals , 1995, The Journal of experimental medicine.

[20]  S. Fortune,et al.  Ligation of CD40 on fibroblasts induces CD54 (ICAM‐1) and CD106 (VCAM‐1) up‐regulation and IL‐6 production and proliferation , 1995, Journal of leukocyte biology.

[21]  M. Crow,et al.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. , 1996, The Journal of clinical investigation.

[22]  W. Min,et al.  Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1 , 1996, The Journal of experimental medicine.

[23]  C. Burns,et al.  Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. , 1996, Journal of immunology.

[24]  M. Mildner,et al.  CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma. , 1996, The American journal of pathology.

[25]  R. Noelle,et al.  CD40 and its ligand. , 1996, Advances in immunology.

[26]  S. Abramson,et al.  Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. , 1996, Arthritis and rheumatism.

[27]  S. Quaglini,et al.  "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. , 1996, Kidney international.

[28]  R. Ramsey‐Goldman,et al.  Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. , 1996, The Journal of clinical investigation.

[29]  A. Steinberg,et al.  Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis , 1996, Annals of Internal Medicine.

[30]  D. Taub,et al.  Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. , 1997, The Journal of clinical investigation.

[31]  J. Banchereau,et al.  Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. , 1997, Kidney international.

[32]  R. Falk,et al.  Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. , 1997, Kidney international.

[33]  G. Hughes,et al.  Immunosuppressive therapy in lupus nephritis. , 1997, Clinical and experimental rheumatology.

[34]  P. Linsley,et al.  Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. , 1997, Journal of immunology.

[35]  V. D’Agati,et al.  Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. , 1997, Arthritis and rheumatism.

[36]  A. Gharavi,et al.  Significance of IgA antiphospholipid antibodies , 1998, Lupus.

[37]  H. Austin.  Clinical evaluation and monitoring of lupus kidney disease , 1998, Lupus.

[38]  M. Petri.  Hydroxychloroquine: past, present, future , 1998, Lupus.

[39]  D. Balomenos,et al.  Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. , 1998, The Journal of clinical investigation.

[40]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[41]  S. Kalled,et al.  Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. , 1998, Journal of immunology.

[42]  D. Boumpas,et al.  Outcome criteria for lupus nephritis trials: A critical overview , 1998, Lupus.

[43]  M. Petri,et al.  Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease , 1998, Annals of Internal Medicine.

[44]  G. Illei,et al.  CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. , 1999, Journal of immunology.

[45]  J. Piette,et al.  Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. , 1999, Medicine.

[46]  J. Cameron,et al.  The very long-term prognosis and complications of lupus nephritis and its treatment. , 1999, QJM : monthly journal of the Association of Physicians.

[47]  D. Harlan,et al.  Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates , 1999, Nature Medicine.

[48]  L. Rassenti,et al.  The soluble CD40 ligand sCD154 in systemic lupus erythematosus. , 1999, The Journal of clinical investigation.

[49]  M. Gur-Lavi.  Long-term remission with allogenic bone marrow transplantation in systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[50]  F. Cosio,et al.  Mycophenolate mofetil therapy in lupus nephritis: clinical observations. , 1999, Journal of the American Society of Nephrology : JASN.

[51]  G. Illei,et al.  Distinct T Cell/Renal Tubular Epithelial Cell Interactions Define Differential Chemokine Production: Implications for Tubulointerstitial Injury in Chronic Glomerulonephritides , 2000, The Journal of Immunology.

[52]  R. Colvin,et al.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand , 2000, Nature Medicine.

[53]  T. Lehman,et al.  Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. , 2000, The Journal of pediatrics.

[54]  D. Boumpas,et al.  New prospects for treatment of lupus nephritis. , 2000, Seminars in nephrology.

[55]  D. Kono,et al.  Treatment of murine lupus with cDNA encoding IFN-γR/Fc , 2000 .

[56]  S. Mujais,et al.  Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study , 2000, The Lancet.

[57]  J. Ioannidis,et al.  Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. , 2000, Kidney international.

[58]  K. Chan,et al.  Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis , 2000 .

[59]  J. Rosenberg,et al.  Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. , 2001, The Journal of rheumatology.

[60]  G. Illei,et al.  Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis , 2001, Annals of Internal Medicine.

[61]  S. Kalled,et al.  Apoptosis and Altered Dendritic Cell Homeostasis in Lupus Nephritis Are Limited by Anti-CD154 Treatment , 2001, The Journal of Immunology.

[62]  G. Illei,et al.  Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. , 2002, Arthritis and rheumatism.

[63]  R. Furie,et al.  The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[64]  P. Lipsky,et al.  CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[65]  R. Hynes,et al.  CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism , 2002, Nature Medicine.

[66]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .